STOCK TITAN

Nexalin Tech - NXL STOCK NEWS

Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.

Nexalin Technology (NXL) delivers non-invasive neurostimulation therapies for mental health and neurological conditions through its patented transcranial electrical stimulation (TES) and deep intracranial frequency stimulation (DIFS) technologies. This page provides investors and healthcare professionals with centralized access to official updates on clinical trials, regulatory milestones, and strategic initiatives.

Discover timely announcements including FDA clearances, partnerships with medical institutions, and advancements in AI-integrated treatment platforms. All content is sourced directly from company releases to ensure accuracy, with a focus on developments impacting mental health innovation and neurostimulation markets.

Key updates cover device efficacy studies, intellectual property expansions, and revenue model evolution through licensing agreements. Bookmark this page to monitor Nexalin's progress in providing drug-free alternatives for anxiety, depression, and neurological disorders while maintaining compliance with financial disclosure standards.

Rhea-AI Summary

Nexalin Technology (NXL) published a landmark study in the Journal of Alzheimer's Disease demonstrating the effectiveness of their Deep Intracranial Frequency Stimulation (DIFS) technology. The study, involving 46 patients over three weeks, showed significant improvements in brain function and cognitive performance in Alzheimer's patients. Key findings include increased neuronal activity, enhanced brain connectivity, improved blood flow, and sustained cognitive benefits over a three-month follow-up period. The treatment proved safe and well-tolerated, with no serious side effects reported. The study validates DIFS as a potential non-pharmacological treatment option for Alzheimer's disease, which affects over 50 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
none
-
Rhea-AI Summary

Nexalin Technology (Nasdaq:NXL) and Calidi Biotherapeutics will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on October 26, 2024, at 7 p.m. ET. Nexalin's CEO Mark White will discuss their non-invasive neurostimulation technology for mental health treatment, including the Gen-3 HALO Clarity device, targeting a market projected to reach $537 billion by 2030. The technology addresses conditions like insomnia, PTSD, and traumatic brain injuries. Calidi's Chief Business Officer Stephen Thesing will present their oncolytic virotherapy developments for cancer treatment, featuring both systemic and localized approaches with engineered viruses protected by cell-based technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
none
-
Rhea-AI Summary

Nexalin Technology (NXL) has announced plans for a new clinical trial in collaboration with UC San Diego and San Diego VA. The study will evaluate the effectiveness of Nexalin's Gen-3 Halo headset in treating veterans with mild Traumatic Brain Injury (mTBI) using a virtual clinic model. This innovative approach allows patients to receive treatment at home, potentially expanding access to care.

The trial builds on positive results from a previous study using Nexalin's Gen-2 device, which showed significant improvements in MEG signals and pain reduction for mTBI patients. The Gen-3 Halo headset incorporates Nexalin's proprietary Deep Intracranial Frequency Stimulation (DIFS®) technology with an advanced 15 milliamp waveform.

The study will recruit two groups: one receiving treatment with the Nexalin Gen-3 Halo headset and another using a sham device for comparison. It aims to assess changes in brain activity and correlate them with improvements in post-concussion symptoms and neuropsychological test performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.95%
Tags
partnership clinical trial
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) has announced promising results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer's disease. The study, published in Alzheimer's Research & Therapy, showed significant improvements in memory and cognitive function among patients treated with DIFS.

Key findings include:

  • Statistically significant improvement in memory (ADAS-Cog scores)
  • Significant increases in MMSE (p = 0.041) and MoCA (p = 0.025) scores
  • Enhanced neural activity and increased blood flow in the hippocampus
  • Well-tolerated treatment with minor side effects

The study involved 46 patients, with 23 in the DIFS group. Functional MRI scans revealed increased blood flow to hippocampal regions, important for memory function. Nexalin is planning further clinical trials to explore different waveform frequencies and enhance clinical response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.71%
Tags
none
-
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) has appointed Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With over 30 years of experience in the medical device industry, Shelton will oversee clinical studies, quality systems, and regulatory submissions for Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology.

Shelton's extensive career includes leadership roles at Openwater Health, Advanced Sterilization Products, Medtronic, and Smith & Nephew. Her expertise in regulatory compliance, quality assurance, and clinical development will be important as Nexalin pursues global regulatory clearances and FDA Breakthrough Device designations.

CEO Mark White emphasized Shelton's strategic importance in guiding Nexalin through complex regulatory processes and international expansion. Shelton expressed enthusiasm for joining Nexalin, highlighting the potential of DIFS technology to provide drug-free alternatives for mental health treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.24%
Tags
management
-
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) participated in a Congressional roundtable in North Carolina focused on virtual therapeutic options for opioid treatment. The event, hosted by the Breaking Barriers for Substance Use Recovery initiative, featured key healthcare and policy stakeholders. Congressman Dr. Greg Murphy, the only practicing physician in Congress, led discussions on deploying virtual-based opioid therapy models nationwide.

Nexalin's approach to virtual therapeutic solutions, pending FDA clearance, was highlighted as a promising tool against opioid addiction. The company's non-invasive neurostimulation technology aims to revolutionize addiction treatment, especially for veterans in rural communities. The roundtable emphasized establishing stronger practices within the VA and SAMHSA to encourage the adoption of virtual-based therapies, expanding the reach and impact of mental health care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.31%
Tags
none
Rhea-AI Summary

Nexalin Technology, Inc. (Nasdaq: NXL) and LOBO EV Technologies (Nasdaq: LOBO) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV on July 27, 2024, at 7 p.m. ET. Nexalin CEO Mark White will provide a corporate update, highlighting the company's non-invasive neurostimulation technology for mental health treatment. Nexalin's Gen-3 HALO™ Clarity device offers an alternative to traditional pharmacological treatments for conditions like insomnia, PTSD, and traumatic brain injuries. The mental health treatment market is projected to reach $537 billion by 2030.

LOBO EV's independent director Harry Schulman will also provide a corporate update. LOBO EV manufactures and sells electric vehicles, including e-bicycles and e-mopeds, focusing on mobility solutions for the elderly and disabled. The Chinese e-bike market is expected to grow from $16 billion to $31.3 billion in the next five years, with a CAGR of 11.76%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
none
-
Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) has been selected as a founding member of Breaking Barriers to Substance Use Recovery, a coalition focused on addressing opioid use disorder in the USA. The organization aims to identify and dismantle obstacles to effective treatment through advocacy, policy solutions, and public education campaigns.

CEO Mark White participated in the inaugural meeting in Washington D.C. in June 2024, joining other industry leaders. The coalition plans to deploy Nexalin's neurostimulation technologies to provide accessible and innovative treatment for those affected by the opioid epidemic.

A key focus of the organization is advocating for Virtual-Based Opioid Treatment (VBOT), which aims to overcome traditional barriers to treatment, especially for veterans and rural communities. The initiative seeks to create a model using innovative virtual technologies and services, coupled with AI and data-driven methodologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
none
-
Rhea-AI Summary

Nexalin Technology closed a public offering of 3,000,000 shares of common stock at $1.75 per share, raising approximately $5.25 million in gross proceeds before fees and expenses. The offering was facilitated by Maxim Group as the sole placement agent.

The shares were registered under a Form S-1 registration statement, which the SEC declared effective on June 27, 2024. A final prospectus was filed on June 28, 2024, and the offering concluded on July 1, 2024.

This announcement does not constitute an offer or solicitation to sell these securities in any jurisdiction where such would be unlawful.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
Rhea-AI Summary

Nexalin Technology announced the pricing of a $5.2 million public offering, involving 3,000,000 shares of common stock at $1.75 per share. The company expects to generate gross proceeds of approximately $5.25 million before fees and expenses. Maxim Group is the sole placement agent for this offering, which is scheduled to close on July 1, 2024, contingent on standard closing conditions. This offering was made under a registration statement declared effective by the SEC on June 27, 2024. The final prospectus will be filed with the SEC, and copies can be obtained from Maxim Group

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.91%
Tags
Nexalin Tech

Nasdaq:NXL

NXL Rankings

NXL Stock Data

22.46M
10.55M
18.59%
2.79%
2.66%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
HOUSTON